# AavantiBio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/aavantibio

- Industry: Biotechnology
- Headquarters: Gainesville, US
- Website: www.aavantibio.com
- Total disclosed funding: $42M
- Latest round: Series A (Oct 21, 2020)
- Investors on record: 4

## About

AavantiBio, Inc., based in the US, is a biotechnology company focused on developing innovative solutions for cellular therapies and regenerative medicine, enhancing biomanufacturing processes for various therapeutic applications.Founded in 2019 in Gainesville, US, AavantiBio specializes in the advancement of biotechnological solutions. The company has completed 2 deals, with its most recent funding occurring on September 30, 2022, during a Series A round that raised USD 41.75 mn from investors including Bain Capital Life Sciences and Perceptive Advisors. AavantiBio is led by CEO Bo Cumbo, who has a history in the biotech sector, assisting in the growth of innovative solutions for healthcare.AavantiBio specializes in the development of innovative biotechnological solutions aimed at advancing cellular therapies and regenerative medicine. Their core product offerings include proprietary platforms designed for enhancing cell culture processes and optimizing therapeutic cell lines, which improve cell yield and functionality in oncology, immunotherapy, and tissue engineering. Their clients, primarily research institutions and pharmaceutical companies across North America and Europe, utilize AavantiBio's advanced biomanufacturing solutions in clinical and commercial applications.AavantiBio generates revenue through a combination of direct sales and strategic partnerships, typically engaging clients via subscription models or project-based contracts. Transactions often involve long-term collaborations where clients leverage AavantiBio’s proprietary technologies for therapy development and manufacturing enhancements. Specific pricing plans are tailored to meet unique client needs, contributing to the company’s revenue particularly through flagship offerings aligned with the demand for innovative solutions in cell therapy and regenerative medicine.Following its acquisition by Solid Biosciences Inc. on September 30, 2022, AavantiBio plans to further develop its neuromuscular and cardiac research initiatives. The recent funding from the Series A round will support the expansion of its research and product development, particularly focusing on new therapeutic solutions. AavantiBio aims to broaden its market presence by targeting new geographic regions and expanding its product offerings in the biotechnology space to meet the increasing demands of the industry.

## Funding rounds

- Series A, Oct 21, 2020, $42M — RA Capital Management, Perceptive Advisors, Bain Capital Life Sciences, Sarepta Therapeutics, Inc.

## Investors

- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series A
- Perceptive Advisors (https://capitalatlas.ai/funds/perceptive-advisors) — Series A
- Bain Capital Life Sciences — Series A
- Sarepta Therapeutics, Inc. — Series A